Tiba Biotech Appoints Dr. Christian W. Mandl as Chairman of Company’s Scientific Advisory Board

CAMBRIDGE, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Tiba Biotech, a pre-clinical biotechnology company developing next generation RNA vaccines for human and animal health, today announced that Christian W. Mandl Ph.D., M.D., an internationally renowned molecular and clinical virologist, has been appointed as Chairman of Tiba’s Scientific Advisory Board. Today’s designation expands upon Mandl’s existing role as Co-founder and Senior Scientific Advisor, Tiba Biotech, as he will take an active role in shaping the Company’s R&D strategy.

“Dr. Mandl brings vast experience in the field of RNA research and is widely recognized as a leader in replicon vaccines,” said Karl Ruping, CEO, Tiba Biotech. “He is a tremendous asset for Tiba and we are thrilled to have him as Chairman of our Scientific Advisory Board. His insights and direction will accelerate the development of our pipeline of vaccine candidates, utilizing our unique delivery system.”

A leading visionary in the field of self-amplifying RNA, Dr. Mandl most recently served as Senior Vice President of RNA technologies at Vir Biotechnology. He previously served as Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines in Cambridge, Massachusetts, leading over 300 discovery and clinical researchers in the development of a broad range of viral and bacterial vaccines, adjuvants and delivery platforms, including self-amplifying mRNA vaccines.  Dr. Mandl was a Professor and Assistant Head of the Clinical Institute of Virology at the Medical University of Vienna where his early replicon research set the foundation for Tiba’s innovative vaccine platform. He has authored more than 100 scientific publications and patents, and is widely recognized for his seminal work in the field of RNA replicons.

“Tiba’s transformative delivery technology addresses key challenges of state-of-the-art methods to introduce engineered nucleic acid into patients, enabling the development of highly efficient RNA vaccines and therapeutics,” stated Dr. Christian Mandl, M.D., PhD, Chairman, Tiba Biotech’s Scientific Advisory Board. “As such, I am very pleased to chair the Scientific Advisory Board and continue to work with the Tiba team to advance the Company’s vaccine candidates to clinical trials.”

About Tiba Biotech
Tiba Biotech is a pre-clinical stage biotechnology company revolutionizing the design and delivery of a safer, more effective and affordable generation of nucleic acid products for human and animal health. Tiba’s innovative RNA vaccine platform disrupts existing design, delivery and bio-manufacturing processes while enabling the rapid development of highly effective vaccines against multiple diseases. Privately held, Tiba is headquartered in Cambridge, Massachusetts, emanated from the Massachusetts Institute of Technology’s Koch Institute, and has strategic partnerships with the U.S. Army Medical Research Institute of Infectious Diseases and a growing list of leading research institutions. To learn more about Tiba, visit www.tiba.bio and follow us on LinkedIn.

Media Contact:
Colette Cote for Tiba Biotech

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b5347796-35b2-4d78-b64a-a3c7e7df5538